- Stocks
- Pharma & Healthcare
- OXYGENTA PHARMA
OXYGENTA PHARMA share price
NSE: OXYGENTAPHPharma & HealthcareDrug Manufacturers - Specialty & Generic
OXYGENTA PHARMA at a glance
With a market capitalisation of ₹185 Cr, it ranks 2321st by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
Its return on equity was 0.0% in FY25. Promoters held 56.54% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹185 CrRank 2321 on NSE
- Price to book
- -11.76×FY25
- ROE
- 0.0%FY25
- ROCE
- 391.4%FY25
- Debt to equity
- -2.49FY25
- Net profit margin
- −8.9%FY25
- Book value / share
- −₹6.77FY25
Returns to 21 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
OXYGENTA PHARMA financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹14 Cr | ₹52 Cr | ₹61 Cr | ₹31 Cr | ₹40 Cr | ₹109 Cr |
| Operating profit | −₹10 Cr | ₹1 Cr | −₹1 Cr | −₹11 Cr | −₹14 Cr | −₹11 Cr |
| Net profit | −₹6 Cr | ₹3 Cr | −₹1 Cr | −₹12 Cr | −₹3 Cr | −₹10 Cr |
| EPS (₹) | −₹5.67 | ₹2.87 | −₹0.48 | −₹8.15 | −₹1.09 | −₹2.69 |
| Cash from operations | −₹7 Cr | −₹2 Cr | −₹2 Cr | −₹2 Cr | −₹13 Cr | ₹3 Cr |
| Total debt | ₹25 Cr | ₹45 Cr | ₹51 Cr | ₹63 Cr | ₹49 Cr | ₹22 Cr |
| Shareholders' equity | −₹41 Cr | −₹38 Cr | −₹35 Cr | −₹46 Cr | −₹20 Cr | −₹25 Cr |
OXYGENTA PHARMA shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 51.12% | 57.92% | 57.95% | 55.93% | 56.54% | 56.54% |
| Domestic institutions | 0.03% | 0.03% | 0.03% | 0.03% | 0.03% | 0.03% |
| Non-institutions | 48.85% | 42.06% | 42.02% | 44.04% | 43.44% | 43.44% |
OXYGENTA PHARMA vs peers
The listed Pharma & Healthcare companies nearest to OXYGENTA PHARMA by market capitalisation.
Ask anything about OXYGENTA PHARMA
Pivot answers on the live chart with evidence you can check, and tests strategies against OXYGENTAPH's own history. Try: “Why has OXYGENTAPH moved over the last three months?” · “Backtest a 50-day moving-average crossover on OXYGENTAPH over five years” · “Compare OXYGENTAPH with CORALAB on margins and valuation”
Frequently asked questions about OXYGENTA PHARMA
What is the market cap of OXYGENTA PHARMA?
OXYGENTA PHARMA's market capitalisation is ₹185 Cr (₹185 Cr) at the 21 Oct 2026 close, ranking 2321st among the NSE companies Pivot tracks.
What is the ROE and ROCE of OXYGENTA PHARMA?
Return on equity was 0.0% in FY25 and return on capital employed was 391.4% in FY25 (standalone figures).
Is OXYGENTA PHARMA a debt-free company?
OXYGENTA PHARMA is close to debt-free: its debt-to-equity ratio was -2.49 in FY25.
What is the shareholding pattern of OXYGENTA PHARMA?
As of 30 Jun 2026: promoters 56.54%, domestic institutions 0.03%, non-institutions 43.44%.
Who are OXYGENTA PHARMA's competitors?
The listed Pharma & Healthcare companies closest to OXYGENTA PHARMA by market cap are Coral Labs, Aashka Hospital, Accretion Nutra, Brooks Laboratories, Earkart and Novelix Pharma.
Is OXYGENTA PHARMA a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out OXYGENTA PHARMA's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on OXYGENTAPH against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 21 Oct 2026 (returns and ratios at the 21 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with O · all NSE stocks · this page as text